JORGE RAICHMAN: Open Payments
NPI 1093740979 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,327 in 41 payments from 9 companies in 2025. Trend: 2023 $2,882 · 2024 $1,535 · 2025 $1,327
Food & beverage: $1,327
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 14 | $499 |
| Janssen Pharmaceuticals, Inc | 6 | $292 |
| Alkermes, Inc. | 8 | $201 |
| Teva Pharmaceuticals USA, Inc. | 4 | $156 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| Lundbeck LLC | 1 | $29 |
| ABBVIE INC. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: COBENFY, INVEGA, ARISTADA, INVEGA SUSTENNA, AUSTEDO XR, REXULTI, UZEDY, FANAPT.
Industry payments across TX — which companies pay providers there.
